Vactosertib
Solid tumors and myelodysplastic syndromes; fibrosis indications in research
- CAS No.
- 1352608-82-2
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Fibrosis
- Target / Mechanism
- TGFBR1
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A TGF-beta pathway inhibitor valuable both as an immuno-oncology combination component and in fibrosis, a dual-track development asset.
Oncology / Fibrosis · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Vactosertib exerts its effects by inhibiting a key cellular signaling pathway called TGF-β, thereby achieving dual anti-tumor and anti-fibrotic effects. It is currently undergoing multiple clinical trials to evaluate its efficacy in treating various solid tumors such as esophageal adenocarcinoma, and osteosarcoma,either alone or in combination with chemotherapy and immunotherapy (such as pembrolizumab).
Supply source: Unibest · Vactosertib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.